^
3d
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
This study demonstrates the feasibility, safety and preliminary efficacy of MEDI5395 with durvalumab in patients with advanced solid tumors.
P1 data • Journal • Combination therapy • Oncolytic virus • Metastases
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CSF2 (Colony stimulating factor 2)
|
Imfinzi (durvalumab) • MEDI5395
over1year
Trial completion • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over2years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=39, Active, not recruiting, MedImmune LLC | Trial completion date: May 2023 --> Dec 2022
Trial completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
almost3years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=39, Active, not recruiting, MedImmune LLC | Trial primary completion date: May 2023 --> Nov 2021
Clinical • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
3years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=38, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting | N=188 --> 38 | Trial completion date: May 2025 --> May 2023 | Trial primary completion date: May 2025 --> May 2023
Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=164, Recruiting, MedImmune LLC | Active, not recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (clinicaltrials.gov)
P1, N=164, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Imfinzi (durvalumab) • MEDI5395
over4years
[VIRTUAL] A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors (AACR-I 2020)
Secondary objectives include assessing MEDI5395 pharmacokinetics (viremia and GM-CSF transgene expression), pharmacodynamics in the TME, immunogenicity, and initial efficacy in combination with durvalumab. The trial is actively accruing.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
IFNG (Interferon, gamma) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression • IFNG expression
|
Imfinzi (durvalumab) • MEDI5395